Literature DB >> 19046314

Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.

L Wu1, X Li, C Chang, S Ying, Q He, Q Pu.   

Abstract

Immunemediated hematopoietic suppression has been considered as one of significant pathophysiological changes in less-advanced myelodysplastic syndrome (MDS). To explore deviation of T cell subsets and its relationship to marrow cells apoptosis, measurement of helper-T (Th)/cytotoxic-T (Tc) subsets as well as the deviation situation within this two subsets (Th1/Th2 and Tc1/Tc2) in marrow was performed by flow cytometry from 39 MDS patients and 13 normal controls. Interferon (INF)-gamma and tumor necrosis factor (TNF)-alpha in marrow serum was simultaneously detected by ELISA (enzyme-linked immunosorbent assay). Furthermore, apoptosis rate of marrow cells was demonstrated by TUNEL (TdT-mediated dUTP nick end labeling). Results showed that Th and Tc subsets were unevenly activated, both deviating to type I response, which was especially obvious in patients with RCMD (according to WHO classification) and in lower-risk cases defined by International Prognosis Scoring System (IPSS). Level of INF-gamma/TNF-alpha in MDS marrow serum was markedly elevated, and so did the apoptosis rate of marrow cells. Although type I deviation was observed both in Th and Tc subsets, just Th1 cell percentage showed positive correlation with level of INF-gamma/TNF-alpha and apoptotic index of nucleated cells. In addition, cytokines level in marrow serum presented positive correlation to apoptosis. We then deduced that the increased Th1 cells in marrow may account for nucleated cells apoptosis in MDS through overproduced proapoptotic cytokines such as INF-gamma and TNF-alpha. Our results suggested that type I deviation of T cell subsets may play a role in pantocytopenia in MDS and the deviation pattern may be as a direct and effective parameter to predict response of immunosuppression therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046314     DOI: 10.1111/j.1751-553X.2007.00970.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  5 in total

1.  Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells.

Authors:  Jing Li; Lanzhu Yue; Huaquan Wang; Chunyan Liu; Hui Liu; Jinglian Tao; Weiwei Qi; Yihao Wang; Wei Zhang; Rong Fu; Zonghong Shao
Journal:  J Immunol Res       Date:  2016-09-19       Impact factor: 4.818

2.  The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Authors:  Astrid Olsnes Kittang; Kristoffer Sand; Annette Katharina Brenner; Kristin Paulsen Rye; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

Review 3.  The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.

Authors:  Nora Chokr; Rima Patel; Kapil Wattamwar; Samer Chokr
Journal:  Adv Hematol       Date:  2018-11-01

4.  Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.

Authors:  Xiao Li; Zhi-jian Xiao; Chun-kang Chang; Feng Xu; Ling-yun Wu; Qi He; Ze-feng Xu; Lu-xi Song; Zheng Zhang; Li-yu Zhou; Ji-ying Su; Xi Zhang; Juan Guo
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

Review 5.  Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.

Authors:  Jing Ming; Wei-Yi Liu; Hai-Yan Xiao; Yong-Gang Xu; Rou Ma; Xiao-Mei Hu
Journal:  Chin J Integr Med       Date:  2020-03-07       Impact factor: 2.626

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.